Targeted Radiation (SBRT) Can Control Prostate Cancer That Has Spread Slightly, Trial Results Suggest

Targeted Radiation (SBRT) Can Control Prostate Cancer That Has Spread Slightly, Trial Results Suggest
Stereotactic body radiation therapy (SBRT) — a form of targeted, high-dose radiation therapy — significantly extends the time without detectable disease progression when given to prostate cancer patients with limited metastatic lesions, data from a Phase 2 trial show. These findings were presented at the recent 2019 American Society for Radiation Oncology (ASTRO) Annual Meeting in Chicago, in the presentation "Primary outcomes of a phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE)" (LBA 3). Radiation has previously been demonstrated to be an effective treatment for prostate cancer that has not spread. However, whether this treatment is effective for oligometastatic prostate cancer — cancer that has spread to a limited number of places in the body — remains unclear. The ORIOLE Phase 2 trial (NCT02680587) was designed to address this in prostate cancer patients whose cancer had returned after surgery or radiation treatment, and who had one to three metastatic lesions outside the prostate. It included 54 men with recurrent hormone-sensitive prostate cancer, who were were randomized to one of two groups: one received no additional treatment and was observed for six months; the other was treated with SBRT targeted a
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *